Drug price inflation slows under investor strategy

Drug prices are still rising in 2020, but the rate of inflation appears to be slowing down. For investors, however, that might be good news, according to The Wall Street Journal.

At the turn of the year, several major drugmakers hiked prices on thousands of drugs––2,167 drug price increases, according to Morgan Stanley analysts cited by the Journal. That’s up 17% from the same time period last year. The increases were “fairly mild,” the Journal noted, with most price increases below 10% and half less than 5%.

While the short-term gains might be lower for investors banking on higher drug prices, the long-term strategy may pay off with the 2020 election. Investors may be looking to lay low to avoid additional scrutiny from Washington, D.C. prior to the election by keeping drug price inflation down.

“With an election looming, investors should be willing to accept a loss of short-term earnings power to avoid attracting unwanted attention from Washington and the resultant threats to the industry’s business model,” the WSJ wrote.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Mark Isenberg, executive vice president of Zotec Partners, discusses key developments that will reshape the specialty this year.